Report Categories
View AllRecent Articles
View All
AEYE AudioEye notches 145 yearoveryear Q4 2025 revenue gain even with EPS miss shares rise modestly
ZYME Zymeworks reports 389 YoY revenue rise even as Q4 2025 EPS falls short of analyst estimates
GJH Synthetic does not report concrete quarterly earnings or revenue figures in its latest release
Is Calumet CLMT stock breaking out today Underperforming 20260420
Gates Foundation Governance Review and Operational Restructuring Update
What Skycorp PN management focus reveals about priorities 1904 20260506
Why CompX CIX is trading below its true worth Investor Concern 20260508
How TPG MITN manages counterparty exposure Q1 2026 Profit Exceeds Views
Snowflake Inc SNOW Former Leadership Backs JuliaHubs 65M Series B Agentic AI for Industrial Digital Twins Signals Emerging Enterprise Tech Vertical Opportunities
HCM III HCMAU Holds 1032 Direction Awaited 20260518
NextEra Energy to Acquire Dominion Energy in Historic Utility Sector Combination
NXG NXG Gains 078 Support Holds at 5713 20260514
Alphabets Google IO AI Showcase Can It Sustain Wall Streets Renewed Confidence
Cricut CRCT Reports Strong Q1 2026 Revenue NA EPS Beats
United Bankshares UBSI RangeBound at 4327 Bulls and Bears in Balance 20260521
First Hawaiian FHB Q1 2026 Results Top Views on Strong Revenue
Zydus Lifesciences Shares Gain on Robust Q4 Results with Buyback Announcement
GE Q1 2026 Earnings EPS Beat Drives Slight Stock Uptick Amid Operational Focus
STSS Q3 2025 Earnings EPS Misses Estimates by a Wide Margin as Revenue Remains Unreported
MVB Financial Corp Q1 2026 Earnings Earnings Beat Expectations Amidst Modest Revenue Headwinds
Flowserve Q1 2026 Earnings EPS Beat Drives Modest Share Gains as Management Highlights Operational Execution
GBDC Q1 2026 Earnings Significant EPS Miss Amid Challenging Market Conditions
Reinsurance Group of America 575 FixedtoFloating Debentures RZB Edge Higher at 2529 Steady Yield Play Nears Key Resistance
Logistic Properties of the Americas LPA Holds Steady Near Support After Modest Gain
Dorman Products DORM Edges Lower Amid Consolidation Near Midpoint of Range
Acumen Pharmaceuticals ABOS Slides 359 Testing NearTerm Support